icon3

Interleukins Market By Product Type (IL-1, IL-6, Others), By Application (Arthritis, Psoriasis, Others) Regional Analysis & Forecast - 2026

  • OI-105
  • |
  • Published date: May, 2019
  • |
  • Life Sciences & Healthcare
  • |
  • 0 Pages

Interleukin (IL) is a group of cytokines that are synthesized by lymphocytes, monocytes, macrophages, and other cells. They regulate cell growth, cell differentiation, and cell motility. Fifteen different types of interleukin are present in the body. The interactions between immune cells and inflammatory cells are mediated by interleukins (IL) proteins. Several interleukins have been described; each has unique biological activities as well as some that overlap with the others that includes IL 1 until IL 38. The understanding of each of the interleukin structure and function leads to new and important insights into the fundamental biology of inflammation and immunity, so play an important role in fighting cancer, infectious disease, and other diseases.


Market Overview


The global Interleukin Inhibitors market valued at xx million US$ in 2018 is anticipated to reach US$ of xx million by the end of 2026, that is growing at a CAGR of xx% during 2018-2026. The factors that influence the Interleukin market are the market environment that involves government policies, technological changes, and market risks. The growing demand for the interleukins for immunological based and cancer treatments, the reduction in the cost of the interleukin therapeutics, the existing market opportunities and challenges towards developing new therapeutics by using different therapies are the major driving factors influencing the global market growth.


Anakinra, Daclizumab (Phase II clinical trial has been completed for its possible use in Multiple Sclerosis), Basiliximab, Tocilizumab, Aldesleukin are some of the interleukin therapeutic recombinant monoclonal antibodies. Pitrakinra, Mepolizumab, Tralokinumabi (Phase II trial is undergoing to evaluate in patients with active, moderate-to-severe ulcerative colitis), Lebrikizumab (successful Phase II clinical trial) are the newer interleukin inhibitors. Therapeutic targeting of IL considered being a rational treatment strategy and promising biologic therapy. Research is continuing with an aim to develop new therapies and refine those already in use. IL-2 acts as novel targets for several autoimmune diseases. IL-1B converting enzyme inhibitors decrease the death rate in severe acute experimental pancreatitis as promising future studies. IL-1R antagonist appears as the new therapy in type 2 diabetes mellitus.


However, the interaction between different molecular pathways, dual action of cytokines, technical problems in the production of interleukins and severe immunological adverse effects are the potential problems that are facing today. These limitations as well as, the proper sequence or combination of different treatment modalities like chemotherapy, cancer vaccines, monoclonal antibodies, and interleukin based treatments and long term effect of these immunological treatments, are among the questions that have to be answered yet and that needs more basic and clinical studies.


Key Developments



  • In March 2019, CHMP recommends approval of AbbVie and Boehringer Ingelheim’s Skyrizi (risankizumab) for Plaque psoriasis in the European Union.

  • In March 2019, Regeneron Pharmaceuticals, Inc and Sanofi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommends for the approval of Dupixent® (dupilumab) for Asthma Indication.


Segmentation


The global interleukin market is segmented on the basis of the product type, end-user/application, and region.


On the basis of product type, Interleukin market is primarily split into IL-1, IL-6, IL-10, and others.


On the basis of applications, Interleukin market focuses on Tumor Therapy and Others. Increase in the prevalence of chronic inflammatory diseases such as arthritis, psoriasis, and asthma is a major factor fueling the global interleukin inhibitors market.


Geographically, this market is segmented into several key Regions covering: Europe, North America, Asia-Pacific, South America, Middle East, and Africa. North America is anticipated to hold the largest share of the global market, due to a rise in the patient pool suffering from psoriasis, arthritis, asthma, and other chronic inflammatory diseases. The presence of well-established drugs makers in North America is further expected to boost the market in the region.


Various contributors that are involved in the value chain of Interleukin market include manufacturers, suppliers, intermediaries, distributors, and customers.


The key manufacturers in the Global Interleukin market include Merck & Co, Novartis Pharma, Abnova, Cayman Chemical, Cell Signaling Technology, Advanced Biotechnologies Inc, Thermo Fisher, and others

The report covers in-depth analysis on Global Interleukins Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (cancer, arthritis, psoriasis, asthma, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.


The report includes in-depth company profiles of key players in Global Interleukins Market. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.


The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.


Scope:



  • Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Interleukins

  • Provides a comparative analysis of key marketed products and pipeline market products.

  • Provides key information on players involved on the Global Interleukins

  • Provides a complete overview of market segments and the regional outlook of Global Interleukins

  • Provides in-depth coverage of key news related toGlobal Interleukins Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:




  • Data Collation (Primary & Secondary)




  • In-house Estimation (Based on proprietary databases and Models)




  • Market Triangulation




  • Forecasting




  • Market-related information is assembled from both primary and secondary sources.








  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 








  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 







  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 



REPORT YOU MIGHT BE INTERESTED

Choose Licence Type

$3,850.00
$4,950.00


(For Corporate Licence Only) Complementary
Credit card Logo
Inquiry Before Buying

Related Reports


Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)